Edition:
United Kingdom

Clementia Pharmaceuticals Inc (CMTA.OQ)

CMTA.OQ on NASDAQ Stock Exchange Global Select Market

13.93USD
8:59pm GMT
Change (% chg)

$0.43 (+3.19%)
Prev Close
$13.50
Open
$13.55
Day's High
$14.18
Day's Low
$13.55
Volume
22,391
Avg. Vol
15,092
52-wk High
$20.12
52-wk Low
$11.77

Latest Key Developments (Source: Significant Developments)

Clementia Initiates Pivotal Phase 3 MOVE Trial For Palovarotene
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Clementia Pharmaceuticals Inc ::CLEMENTIA INITIATES PIVOTAL PHASE 3 MOVE TRIAL FOR PALOVAROTENE IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA.CLEMENTIA PHARMACEUTICALS INC - COMPLETION OF ENROLLMENT FOR PHASE 3 MOVE TRIAL EXPECTED BY END OF 2018.  Full Article

Clementia Pharmaceuticals qtrly loss per share ‍$1.83​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Clementia Pharmaceuticals Inc ::Clementia Pharmaceuticals Inc - qtrly loss per share ‍$1.83​.Clementia Pharmaceuticals Inc- ‍as of September 30, 2017, had cash and investments of $152.2 million​.Clementia - ‍anticipates reporting preliminary results from part b open-label extension portion of phase ii study of palovarotene in fop in Q2 2018​.Clementia Pharmaceuticals Inc- on track to begin move study protocol phase iii study and enroll first patient by end of 2017​.  Full Article

BRIEF-Clementia Initiates Pivotal Phase 3 MOVE Trial For Palovarotene

* CLEMENTIA INITIATES PIVOTAL PHASE 3 MOVE TRIAL FOR PALOVAROTENE IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA